Bologna

• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie … Ended
  2022-501261-46-00 4 2023-04-14 Relapsed/Refractory Burkitt Lymphoma (BL)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501262-21-00 4 2023-04-14 Relapsed/Refractory Hairy Cell Leukemia
• A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w … Ended
  2022-501451-87-00 9 2023-03-31 Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
• Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate … Ended
  2024-513584-77-00 4 2023-03-09 Primary biliary cholangitis
• Multiple Dose Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of MYK-224 in Participants with Sympto … Ended
  2023-508831-29-00 4 2023-02-15 Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow T
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 4 2023-02-14 Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or F
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphoma Ended
  2022-501431-16-00 4 2023-01-17 Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lympho
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended
  2024-513885-20-00 4 2022-12-05 Insomnia Disorder
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 BRCA Mutations and Early Stage HER2-Negative Breast Cancer
• A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended
  2023-506772-28-00 4 2022-10-07 Ewings Sarcoma
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabi … Ended
  2024-516388-10-00 9 2022-09-23 Acute Myeloid Leukemia
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s D … Ended
  2023-509835-26-00 4 2022-07-06 Huntington’s Disease

Showing 769–792 of 868 trials